Table 3 Description of entire study cohort

Age, years*

68 (55.7 ~ 78.6)

70.4 (58.3 ~ 79.5)

65.7 (53.5 ~ 77.5)

<0.001

0.239

Female (%)

44.12%

43.73%

44.47%

0.465

0.015

Male (%)

55.88%

56.27%

55.53%

0.465

0.015

Transfused patients (%)

46.76%

100.00%

0.00%

---

---

Nadir hematocrit, percentage*

25.7 (23.6 ~ 27.6)

24.8 (22.9 ~ 26.6)

26.6 (24.5 ~ 28.3)

<0.001

0.657

Nadir hemoglobin, percentage*

8.6 (7.8 ~ 9.3)

8.2 (7.5 ~ 9)

8.9 (8.1 ~ 9.5)

<0.001

SAPS I score, point

15 (12 ~ 19)

17 (13 ~ 20)

14 (11 ~ 18)

<0.001

0.464

SOFA score, point

7 (4 ~ 9)

8 (5 ~ 11)

6 (3 ~ 8)

<0.001

0.43

Elixhauser Comorbidity, point

2 (1 ~ 4)

2 (1 ~ 4)

2(1 ~ 4)

<0.001

0.086

Medical patients (%)

29.66%

28.28%

30.87%

0.005

0.057

Acute cardiac patients (%)

12.67%

14.45%

11.11%

<0.001

0.1

Surgical patients, noncardiac (%)

24.21%

22.59%

25.64%

<0.001

0.071

Surgical patients, cardiac (%)

33.46%

34.68%

32.38%

0.016

0.049

Nonacute cardiac patients

26.72%

28.45%

25.20%

<0.001

0.073

Hematologic cancer patients (%)

2.58%

2.90%

2.30%

0.061

0.038

Solid cancer patients (%)

16.06%

16.07%

16.05%

0.979

<0.001

Sepsis patients (%)

15.99%

19.03%

13.31%

<0.001

0.156

GI bleed patients (%)

6.41%

10.18%

3.10%

<0.001

0.287